UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-12111 Pediatrix Medical Group, Inc. (Exact name of registrant as specified in its charter) Florida 26-3667538 (State or othe ...

Pediatrix Medical Group, Inc. (NYSE:MD) Q4 2022 Earnings Conference Call February 17, 2023 9:00 AM ET Company Participants Charles Lynch ??? Senior Vice President, Finance and Strategy Mark Ordan ??? Executive Chair Jim Swift ??? Chief Executive Officer Marc Richards ??? Chief Financial Officer Conference Call Participants Jack Senft ??? William Blair AJ Rice ??? Credit Suisse Pito Chickering ??? Deutsche Bank Whit Mayo ??? SVB Securities Kevin Fischbeck ??? Bank of America Rishi Parekh ??? JPMorgan Tao Qi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from to Registrant's telephone number, including area code (954) 384-0175 Securities registered pursuant to Section 12(b) of the Act: | Title of Each Class | Trading Symbol | Name of Each Excha ...

Pediatrix Medical Group, Inc. (NYSE:MD) Q3 2022 Earnings Conference Call November 3, 2022 9:00 AM ET Corporate Participants Charles Lynch - Investor Relations Mark Ordan - Chief Executive Officer Marc Richards - Chief Financial Officer James Swift - Chief Operating Officer Conference Call Participants Pito Chickering - Deutsche Bank Whit Mayo - SVB Securities Tao Qiu - Stifel Kevin Fischbeck - Bank of America Brian Tanquilut - Jefferies AJ Rice - Credit Suisse Operator Ladies and gentlemen, thank you for st ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Commission File Number: 001-12111 Pediatrix Medical Group, Inc. (Exact name of registrant as specified in its charter) Florida 26-3667538 (State or other jurisdiction of Incorporation or organization) OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ...

Pediatrix Medical Group, Inc. (NYSE:MD) Q2 2022 Earnings Conference Call August 4, 2022 9:00 AM ET Corporate Participants Charles Lynch - Investor Relations Mark Ordan - Chief Executive Officer Marc Richards - Chief Financial Officer Conference Call Participants Tao Qiu - Stifel Brian Tanquilut - Jefferies Kevin Fischbeck - Bank of America Pito Chickering - Deutsche Bank Whit Mayo - SVB Securities Ryan Daniels - William Blair AJ Rice - Credit Suisse Operator Ladies and gentlemen, thank you for standing by, ...

[PART I - FINANCIAL INFORMATION](index=3&type=section&id=PART%20I%20-%20FINANCIAL%20INFORMATION) [Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) Financial statements show decreased cash and assets from debt refinancing, and lower net income due to debt extinguishment - On July 1, 2022, the company changed its corporate name from "Mednax, Inc." to **Pediatrix Medical Group, Inc.** to reflect its core focus on care for women, babies, and children[19](index=19&type=chunk) [Consolidated Balance Sheets](index=3&type=section&id=Consolidated%20Balance%20Sheets) Total assets decreased to **$2.37 billion** from **$2.72 billion**, driven by reduced cash for debt refinancing Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2022 | December 31, 2021 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $14,088 | $387,391 | | Total current assets | $459,301 | $840,564 | | Goodwill | $1,532,092 | $1,505,430 | | Total assets | $2,369,616 | $2,722,546 | | **Liabilities & Equity** | | | | Total current liabilities | $329,415 | $427,366 | | Line of credit | $153,500 | $0 | | Long-term debt and finance lease liabilities, net | $639,754 | $1,002,258 | | Total liabilities | $1,524,186 | $1,825,854 | | Total equity | $845,430 | $896,692 | [Consolidated Statements of Income](index=4&type=section&id=Consolidated%20Statements%20of%20Income) Net revenue increased in Q2 and H1 2022, but net income sharply decreased due to a **$57.0 million** debt extinguishment loss Key Income Statement Data (in thousands, except per share data) | Metric | Q2 2022 | Q2 2021 | H1 2022 | H1 2021 | | :--- | :--- | :--- | :--- | :--- | | Net revenue | $486,033 | $472,959 | $968,262 | $919,712 | | Income from operations | $50,155 | $50,016 | $89,263 | $76,120 | | Loss on early extinguishment of debt | $0 | $0 | $(57,016) | $(14,532) | | Net income attributable to Pediatrix | $27,136 | $35,011 | $5,948 | $52,653 | | Diluted EPS | $0.32 | $0.41 | $0.07 | $0.61 | [Consolidated Statements of Equity](index=5&type=section&id=Consolidated%20Statements%20of%20Equity) Total equity decreased to **$845.4 million** from **$896.7 million**, primarily due to common stock repurchases - The company repurchased **3.3 million shares** of its common stock for **$64.4 million** during the second quarter of 2022[13](index=13&type=chunk) - Retained deficit improved from **$(155.4) million** at year-end 2021 to **$(149.5) million** at June 30, 2022, reflecting the net income generated during the period[8](index=8&type=chunk)[13](index=13&type=chunk) [Consolidated Statements of Cash Flows](index=6&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities was **$15.1 million**, with a **$373.3 million** net decrease in cash due to debt redemption Cash Flow Summary - Six Months Ended June 30 (in thousands) | Activity | 2022 | 2021 | | :--- | :--- | :--- | | Net cash used in operating activities | $(15,075) | $(28,601) | | Net cash (used in) provided by investing activities | $(39,625) | $3,725 | | Net cash used in financing activities | $(318,603) | $(760,810) | | **Net decrease in cash and cash equivalents** | **$(373,303)** | **$(785,686)** | | Cash and cash equivalents at end of period | $14,088 | $338,157 | [Notes to Consolidated Financial Statements](index=7&type=section&id=Notes%20to%20Consolidated%20Financial%20Statements) The notes detail key accounting policies and financial activities, including **$31.3 million** in acquisitions and a major debt restructuring - The company completed the acquisition of one multi-location pediatric urgent care practice and one pediatric gastroenterology and gynecology practice for total consideration of **$31.3 million**, recording **$26.7 million** in goodwill[36](index=36&type=chunk) - In February 2022, the company issued **$400.0 million** of 5.375% senior notes due 2030 and amended its credit agreement to include a **$450 million** revolving credit line and a new **$250 million** term loan, with proceeds used to redeem the **$1.0 billion** 6.25% senior notes due 2027[42](index=42&type=chunk)[44](index=44&type=chunk) - During the six months ended June 30, 2022, the company repurchased **3.3 million shares** of its common stock for **$65.6 million**[58](index=58&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=13&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses financial performance, highlighting revenue growth from acquisitions, same-unit declines, and debt refinancing impacts - The company's operating results have not been materially impacted by COVID-19 or its variants in 2021 or thus far in 2022, though uncertainty remains[66](index=66&type=chunk) - The company is monitoring the impact of the "No Surprises Act," effective January 1, 2022, which could limit amounts recovered for out-of-network services and affect payor contract negotiations[77](index=77&type=chunk)[78](index=78&type=chunk)[79](index=79&type=chunk) Reconciliation to Adjusted EBITDA (in thousands) | Metric | Q2 2022 | Q2 2021 | H1 2022 | H1 2021 | | :--- | :--- | :--- | :--- | :--- | | Income from continuing operations | $30,701 | $30,533 | $9,760 | $35,885 | | **Adjusted EBITDA from continuing operations** | **$65,555** | **$65,533** | **$116,237** | **$111,016** | Reconciliation to Adjusted EPS | Metric | Q2 2022 | Q2 2021 | H1 2022 | H1 2021 | | :--- | :--- | :--- | :--- | :--- | | Diluted EPS from continuing operations | $0.36 | $0.36 | $0.11 | $0.42 | | **Adjusted Diluted EPS from continuing operations** | **$0.47** | **$0.41** | **$0.79** | **$0.65** | [Results of Operations](index=16&type=section&id=Results%20of%20Operations) Net revenue increased in Q2 and H1 2022 from acquisitions, despite same-unit declines, with operating income improving due to lower G&A - **Q2 2022 vs Q2 2021:** - Net revenue increased by **$13.0 million (2.8%)**, primarily from acquisitions - Same-unit net revenue decreased by **$6.1 million (1.3%)**, driven by a **$8.6 million** decrease from reimbursement factors, partially offset by a **$2.5 million** increase from volume[88](index=88&type=chunk) - **H1 2022 vs H1 2021:** - Net revenue increased by **$48.6 million (5.3%)**, primarily from acquisitions - Same-unit net revenue decreased by **$2.8 million (0.3%)**, driven by a **$20.4 million** decrease from reimbursement factors, partially offset by a **$17.6 million** increase from volume[103](index=103&type=chunk)[104](index=104&type=chunk) - General and administrative expenses decreased by **$9.8 million** in Q2 and **$15.0 million** in H1 2022 compared to the prior year, primarily due to lower professional fees and net savings in revenue cycle management expenses[91](index=91&type=chunk)[107](index=107&type=chunk) [Liquidity and Capital Resources](index=19&type=section&id=Liquidity%20and%20Capital%20Resources) Liquidity decreased significantly due to debt refinancing, including new notes and credit agreements, resulting in a **$57.0 million** loss - Working capital decreased by **$283.3 million** from Dec 31, 2021, to **$129.9 million** at June 30, 2022, primarily due to the use of cash for the redemption of the 2027 Notes[118](index=118&type=chunk) - Days sales outstanding (DSO) for continuing operations increased to **58.2 days** at June 30, 2022, from **55.2 days** at December 31, 2021, due to the timing of cash collections[122](index=122&type=chunk) - At June 30, 2022, the company had an outstanding principal balance of **$400.4 million** on its Amended Credit Agreement (**$153.5 million** revolver, **$246.9 million** term loan) and **$400.0 million** on its 2030 Notes[131](index=131&type=chunk)[132](index=132&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=22&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risk is interest rate exposure on its **$400.4 million** variable-rate debt - The company is exposed to interest rate risk on its Amended Credit Agreement, which had a **$400.4 million** balance at June 30, 2022[139](index=139&type=chunk) - A **1%** change in interest rates would result in an approximate annual impact of **$4.0 million** to income before taxes[139](index=139&type=chunk) [Controls and Procedures](index=22&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls and procedures were effective as of June 30, 2022, with no material changes in internal control - The CEO and CFO concluded that disclosure controls and procedures were effective as of June 30, 2022[141](index=141&type=chunk) - No changes occurred during Q2 2022 that have materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting[142](index=142&type=chunk) [PART II - OTHER INFORMATION](index=23&type=section&id=PART%20II%20-%20OTHER%20INFORMATION) [Legal Proceedings](index=23&type=section&id=Item%201.%20Legal%20Proceedings) The company faces ordinary course legal actions, primarily medical malpractice claims, with risk largely self-insured - The company faces legal actions and government inquiries in the ordinary course of business, with most claims related to medical malpractice[145](index=145&type=chunk)[146](index=146&type=chunk) - A significant portion of professional liability risk is self-insured through a wholly owned captive insurance subsidiary[147](index=147&type=chunk) [Risk Factors](index=23&type=section&id=Item%201A.%20Risk%20Factors) No material changes to risk factors were reported since the company's 2021 Annual Report on Form 10-K - No material changes to risk factors were reported since the 2021 Form 10-K[148](index=148&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=23&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) During Q2 2022, the company repurchased **3.3 million shares** of common stock for approximately **$64.4 million** Share Repurchases for Q2 2022 | Period | Total Number Repurchased | Average Price Paid per Share | | :--- | :--- | :--- | | April 1 – April 30, 2022 | — | $ — | | May 1 – May 31, 2022 | 637,000 | $19.04 | | June 1 – June 30, 2022 | 2,637,802 | $19.79 | | **Total** | **3,274,802** | **$19.65** | [Other Information](index=24&type=section&id=Item%205.%20Other%20Information) A new employment agreement for EVP and COO James D. Swift, M.D. was executed, detailing salary, bonus, and severance terms - A new employment agreement for EVP and COO James D. Swift, M.D. was executed on August 1, 2022[153](index=153&type=chunk) - Key terms include a **$450,000** base salary, a **100%** target bonus, and specified severance benefits[153](index=153&type=chunk) [Exhibits](index=25&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including amended articles, employment agreements, and certifications [Signatures](index=26&type=section&id=SIGNATURES)

MEDNAX, Inc. (NYSE:MD) Q1 2022 Earnings Conference Call April 28, 2022 9:00 AM ET Company Participants Charles Lynch - SVP, Finance, Strategy & IR Mark Ordan - CEO & Director Marc Richards - EVP & CFO James Swift - Chief Development Officer Conference Call Participants Tao Qiu - Stifel, Nicolaus & Company A.J. Rice - Cr??dit Suisse Nicholas Spiekhout - William Blair & Company Whit Mayo - SVB Leerink Kevin Fischbeck - Bank of America Merrill Lynch Operator Ladies and gentlemen, thank you for standing by, and ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the transition period from ______ to ______ Commission File Number: 001-12111 Mednax, Inc. (Exact name of registrant as specified in its charter) Florida 26-3667538 (State or other jurisdiction of Incorporation or organization) 1301 Concord Terrace Sunrise, Florida 33323 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION RE ...

Financial Data and Key Metrics Changes - The fourth quarter results were in line with expectations, reflecting a strong recovery from the previous year, with total births at hospitals providing NICU services up 5% and NICU days up 5.6% on a same-unit basis [5][6] - The company recorded significant funds from the CARES Act, totaling $26 million in revenue and $16.5 million in adjusted EBITDA for the quarter [8][9] - The outlook for 2022 includes expected revenue of approximately $2 billion and adjusted EBITDA of at least $270 million, with a focus on efficiency improvements [8][16] Business Line Data and Key Metrics Changes - The company achieved solid results in 2021 compared to pre-pandemic levels, with same-unit volumes growing by roughly 1% despite a 2.5% decline in the first quarter of the previous year [6][8] - The transition of revenue cycle operations to R1 is expected to yield meaningful savings, which began to be seen in Q3 of the previous year [7][9] Market Data and Key Metrics Changes - The payer mix was favorable year-over-year, reflecting a slightly favorable comparison to pre-pandemic levels [5] - The company is focused on expanding its pediatric primary and urgent care clinics, with recent acquisitions in Houston and Orlando [10][11] Company Strategy and Development Direction - The company is transitioning to operate under a unified Pediatrix brand, which is expected to strengthen existing relationships and open new opportunities [12][13] - The company is committed to environmental, social, and governance (ESG) goals, having improved its average ISS ESG quality score from over six to three [14] Management's Comments on Operating Environment and Future Outlook - Management noted that the impact of surprise billing legislation is currently limited due to a strong payer relationship and a diversified contract portfolio [15] - The company has not experienced significant workforce pressures or turnover, although the recruiting environment remains challenging [32] Other Important Information - The refinancing of the capital structure is expected to reduce annual debt service expenses by more than half and lower the weighted average interest rate on borrowings from 6.25% to under 4% [18][19] - The company is evaluating several markets for new clinic openings, with plans to open new clinics before the end of the year [45] Q&A Session Summary Question: Initial evidence from payers regarding surprise billing regulation - Management indicated a mix of responses from payers, with some contracts being renewed at higher rates while others are waiting to see how the situation develops [24] Question: Impact of supply chain issues - Management stated that they are not assuming any impact from surprise billing in their numbers, but expect modifications to the IFR based on feedback received [29] Question: Workforce pressures and inflation - Management reported no material workforce pressures so far, although they acknowledge the tough recruiting environment [32] Question: Update on Brave Care acquisition integration - Integration of Brave Care's technology into existing platforms is ongoing and expected to enhance patient experience in clinics [34] Question: Accounts receivable increase and CMS guidance on newborn screenings - Management explained that the increase in accounts receivable was expected due to the transition of the RCM function, and the impact from CMS changes on newborn screenings was noted but not significant to overall revenue [38][40] Question: G&A guidance and savings opportunities - Management discussed ongoing efforts to streamline operations and the potential for future savings from the RCM outsourcing initiative [42][43]